TBIO Telesis Bio Inc (PK)

Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:

    What: Transgenomic, Inc. First Quarter 2013 Financial Results and Business Update Conference Call   When: Wednesday, May 8, 2013 @ 5:00 p.m. Eastern   Where:

http://www.transgenomic.com/calendar/2013/04/first-quarter-financial-results-conference-call-may-8-2013

  How: Live over the Internet -- Simply log on to the web at the address above.   Contact: Investor Relations, 402-452-5416  

To access the call via telephone, dial 866-952-1907 from the U.S. and Canada or 785-424-1826 for international participants and enter conference ID TRANS. A telephone replay will be available from 8:00 p.m. Eastern Time on May 8, 2013 through 11:59 p.m. Eastern Time on May 22, 2013 by dialing 800-839-1198 (domestic) or 402-220-0458 (international).

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is a global leader in cardiac genetic testing with a family of innovative products, including its C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.